Andere Sprachen Ascentage Pharma Group International

Aktien

A2PUCQ

KYG0519B1023

6855

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:09:09 25.04.2024			% 5 Tage	% 1. Jan.
17,3 ^HKD	+0,46 %		+2,61 %	-36,63 %

11:20	Ascentage Pharma präsentiert vier Studien auf US Onkologie-Treffen	MT
09.04.	Vorsitzender von Ascentage Pharma erhöht Beteiligung am Unternehmen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ascentage Pharma to Present Four Studies at US Oncology Meet	11:20
Ascentage Pharma Chairman Boosts Stake in Firm	09.04.
Ascentage Pharma Group Directors Acquire Company Shares	04.04.
Ascentage Pharma Widens Loss by Nearly 5% in 2023	28.03.
Ascentage Pharma Announces 2023 Annual Results	28.03.
Ascentage Pharma Group International Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Ascentage Pharma to Present Preclinical Results of Three Anti-Tumor Drugs at US Cancer Meet	06.03.
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting	06.03.
Ascentage Pharma's Phase 3 Trial for Chronic Myeloid Leukemia Treatment Gets US FDA Nod; Shares Rise 3%	14.02.
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA	14.02.
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia	14.02.
Ascentage Pharma Trustee Buys 100,000 Shares	05.02.
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia Management from the National Comprehensive Cancer Network	17.01.
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference	02.01.
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib	15.12.
Live from ASH 2023, Ascentage Pharma Releases the First Dataset of Bcl-2 Inhibitor Lisaftoclax in Patients with R/R MM, Demonstrating Encouraging ORR and VGPR	12.12.
Live from ASH 2023, Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib	12.12.
Live from ASH 2023, Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%	12.12.
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR	11.12.
Small Lymphocytic Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 \| Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, and others.	05.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ascentage Pharma Group International

Aktien

A2PUCQ

KYG0519B1023

6855

Andere Sprachen

Filter